Can you get medical cannabis for OCD in the UK?
Obsessive-compulsive disorder has an unusually clear first-line treatment in the UK, and an unusually clear negative result from the one controlled study of cannabis. That makes this a short page with a straightforward answer.
The short answer
- No cannabis-based product is licensed for OCD, and NICE does not recommend one.
- The one controlled study found no significant benefit over placebo.
- Expectation drove the result — people improved whether or not they received an active drug.
- Exposure and response prevention therapy is the treatment with the strongest evidence.
- Avoidance is the mechanism of OCD, and a drug that dampens anxiety can quietly reinforce it.
Is OCD treated with medical cannabis in the UK?
It is occasionally assessed privately, usually where OCD sits alongside severe anxiety. No cannabis-based product is licensed for OCD and NICE guidance does not include cannabis-based medicines among the treatments it recommends.
NICE recommends a stepped approach built around cognitive behavioural therapy including exposure and response prevention, with an SSRI where therapy alone is not enough. Access to that therapy is patchy, and long waits are a real reason people look elsewhere — but the therapy remains the treatment with by far the strongest evidence base.
What the evidence actually shows
There is one controlled human laboratory study. It compared cannabis containing THC, cannabis containing predominantly cannabidiol, and placebo in adults with OCD, and found no significant difference between the active conditions and placebo on obsessions or compulsions.
The study behind that paragraph
Kayser RR, Haney M, Raskin M, Arout C, Simpson HB. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depression and Anxiety. 2020;37(8):801-811. Participants reported reduced anxiety after all three conditions, including placebo, which the authors attributed to expectancy.
That placebo finding is the most useful part of the study for a patient to know. People felt better after taking something they believed would help, regardless of what it was. Any uncontrolled report of cannabis helping OCD has to contend with that explanation first.
The wider systematic review of cannabinoids in mental disorders reached the same conclusion it did elsewhere: insufficient controlled evidence to support use.
What a specialist will want to see
Given a negative controlled study, a specialist assessing OCD is generally looking at whether something else is the real target — severe comorbid anxiety, for instance — rather than at OCD itself.
- Whether OCD has been formally diagnosed, and its severity
- Whether you have been offered CBT with exposure and response prevention, and completed it
- Which SSRIs you have tried, at what dose, and for how long
- Coexisting conditions, particularly anxiety disorders, depression and tics
- Your personal and family history of psychosis
- Any current or past problems with alcohol or other substances
The general requirements — age, a documented diagnosis, the convention that two standard treatments have been tried, and access to your medical records — are covered in What are the requirements?
Risks and reasons a specialist may say no
There is a mechanism-level concern specific to OCD. The disorder is maintained by avoidance: the compulsion relieves the distress, which teaches the brain to repeat it. Anything that reliably reduces distress in the moment can function as another compulsion.
That is not a theoretical worry. It is the reason exposure-based therapy deliberately does the opposite — sitting with the discomfort until it fades on its own. A specialist who understands OCD will be alert to a medicine becoming part of the ritual rather than a way out of it.
The usual cautions apply as well: a personal or family history of psychosis, unstable mental illness, pregnancy or breastfeeding will normally count against treatment, and THC can increase anxiety in some people rather than reduce it.
If you want to take this further
The useful next step is a proper assessment, not a longer reading list. Gather your diagnosis, the treatments you have already tried and what happened with each, and a current list of your medicines — that is what a specialist needs in order to give you a straight answer.
The consultation itself, and what happens after it, is set out in What is the process to get a medical cannabis prescription? If OCD is not the only thing you are being treated for, say so early: other conditions and other medicines change the assessment.
Frequently asked questions
Can I get medical cannabis for OCD in the UK?
It is occasionally assessed privately, usually alongside severe anxiety, but nothing is licensed for OCD and NICE does not recommend it. The one controlled study found no significant benefit over placebo.
What did the OCD study find?
A human laboratory study compared THC-containing cannabis, predominantly cannabidiol cannabis and placebo in adults with OCD. There was no significant difference between them. Participants improved after all three, which the authors attributed to expectation.
What is the recommended treatment for OCD?
NICE recommends cognitive behavioural therapy including exposure and response prevention, with an SSRI where therapy alone is not sufficient. That remains the treatment with the strongest evidence.
Could it make OCD worse?
It might. OCD is maintained by avoidance of distress, so anything that reliably removes distress in the moment risks becoming another compulsion. A specialist who understands OCD will weigh that carefully.
Sources and further reading
Every factual statement on this page is drawn from the following public sources. Links open in a new tab and are not affiliated with Flora House.
- Kayser RR, et al. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: a human laboratory study. Depression and Anxiety (2020)
- Black N, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry (2019)
- NICE guideline CG31: Obsessive-compulsive disorder and body dysmorphic disorder
- NICE guideline NG144: Cannabis-based medicinal products
- NHS: Medical cannabis (and cannabis oils)
- MHRA: The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use